Neuroderm Ltd. (NDRM) 14.04 $NDRM
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 31.68 (-0.33), ABBV: 65.44 (-0.86), NDRM: 14.04 (-4.10), NVS: 92.66 (-0.55)
Market News: Civeo Corp, Eagle Rock Energy Partners, Neuderm Ltd
at The Street - Wed Dec 31, 1:53PM CST
The stock markets in the United States fluctuated declined, wiping out earlier gains today–the last trading session for 2014. The markets were negatively impacted by the weakness of equities in ...
CVEO: 4.11 (+0.19), EROC: 2.20 (+0.18), NDRM: 14.04 (-4.10)
NeuroDerm (NDRM) Stock Plunges Today Following Tuesday's Gains
at The Street - Wed Dec 31, 1:16PM CST
Shares of NeuroDerm (NDRM) plummeted Wednesday as the stock sold off one day after it soared following the company's announcement of encouraging trial results for a treatment of Parkinson's disease.
NDRM: 14.04 (-4.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.03 (-0.62), SIBC: 20.72 (+5.36), FUR: 15.59 (-2.32), DRAM: 1.70 (-0.23), NRX: 13.35 (+8.70), MEIL: 1.36 (+0.35), MIG: 8.46 (+1.33), BCLI: 4.76 (+0.88), ABAC: 1.73 (-0.18), GBR: 1.51 (+0.23), NDRM: 14.04 (-4.10), RCMT: 7.00 (-1.55), AGRX: 6.14 (-0.56), REN: 1.32 (+0.28), KEG: 1.67 (-0.19), LIME: 2.93 (+0.52), CALA: 20.20 (+1.89), CJJD: 2.90 (-0.25), CBMG: 12.91 (+1.39), GNI: 13.90 (-1.90)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 8.01 (+1.11), NEON: 3.38 (+0.30), ARWR: 7.38 (-0.19), NRX: 13.35 (+8.70), PEIX: 10.33 (-0.38), BCLI: 4.76 (+0.88), MIG: 8.46 (+1.33), NDRM: 14.04 (-4.10)
Spot the Potential Winners: Research Reports on SEACOR, Shanda Games, Neuroderm, Seadrill, and Lockheed Martin
PR Newswire - Wed Dec 31, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including SEACOR (NYSE: CKH), Shanda Games (NASDAQ: GAME), Neuroderm (NASDAQ: NDRM) Seadrill (NYSE: SDRL), and Lockheed Martin (NYSE: LMT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
LMT: 192.57 (-2.86), CKH: 73.81 (-0.12), GAME: 5.68 (-0.13), SDRL: 11.94 (+0.01), NDRM: 14.04 (-4.10)
Today's Market: Stocks Making Solid Moves Into New Year
Matthew Smith - at Seeking Alpha - Wed Dec 31, 7:49AM CST
NPD: 1.58 (-0.10), WAB: 86.89 (-1.17), CJJD: 2.90 (-0.25), AAPL: 110.38 (-2.14), NDRM: 14.04 (-4.10)
NeuroDerm up on drug data
at Investor's Business Daily - Tue Dec 30, 5:28PM CST
Positive midstage trial results for its Parkinson's disease candidate ND0612H lifted shares of NeuroDerm (NDRM), which bounced back from its flop stock market debut last month. The biotech said that a high-dose combo of standard Parkinson's drugs...
NDRM: 14.04 (-4.10)
Stocks Fall in Light Trading as Oil and Greece Weigh on Markets
at The Street - Tue Dec 30, 3:09PM CST
Oil and Greece were the focus of 2014's penultimate trading session in what was an otherwise quiet day.
GPRO: 63.22 (-2.18), HK: 1.78 (+0.05), ABX: 10.75 (-0.11), AKAM: 62.96 (-1.11), FCX: 23.36 (-0.22), NEM: 18.90 (-0.36), XNPT: 8.77 (unch), NDRM: 14.04 (-4.10), RDS.A: 66.95 (-0.41), KGC: 2.82 (+0.02), GLD: 113.58 (-1.62), CVEO: 4.11 (+0.19), BP: 38.12 (-0.24), ARCP: 9.05 (-0.06), YELP: 54.73 (+0.49), XLE: 79.16 (-0.60), GG: 18.52 (-0.07)
Market News: Neuroderm Ltd, Civeo Corp, Expedia Inc
at The Street - Tue Dec 30, 2:36PM CST
The stock markets in the United States dropped today. The S&P 500's seventh straight gain in December was trimmed by today's decline, according to Bloomberg. The S&P 500 reached a record-l...
EXPE: 85.36 (-0.61), CVEO: 4.11 (+0.19), NDRM: 14.04 (-4.10)
NeuroDerm Is A Good Play In Parkinson's Disease
Clinically Sound Investor - at Seeking Alpha - Tue Dec 30, 12:39PM CST
NDRM: 14.04 (-4.10)
NeuroDerm Rebounds On Parkinson's Disease Drug Data
at Investor's Business Daily - Tue Dec 30, 11:19AM CST
Recent biotech IPO NeuroDerm (NDRM) on Tuesday bounced back from its flop stock market debut last month after it reported positive midstage trial results for its Parkinson's disease candidate, with shares jumping more than 70%. NeuroDerm said...
IPXL: 31.68 (-0.33), ACOR: 40.87 (+0.23), NVS: 92.66 (-0.55), NDRM: 14.04 (-4.10)
NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results
at The Street - Tue Dec 30, 9:07AM CST
Shares of NeuroDerm (NDRM) soared to a 52-week high in morning trading Tuesday after the Israeli company announced encouraging results from a trial for a treatment of Parkinson's disease.
NDRM: 14.04 (-4.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 8:11AM CST
JOB: 1.21 (-0.01), ARCP: 9.05 (-0.06), CJJD: 2.90 (-0.25), XNPT: 8.77 (unch), NDRM: 14.04 (-4.10)
NeuroDerm LD/CD candidates deliver high levodopa levels in PD patients in study
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 7:25AM CST
NDRM: 14.04 (-4.10)
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
GlobeNewswire - Tue Dec 30, 6:11AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that continuous, subcutaneous delivery of the company's proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for severe Parkinson's disease patients, may provide an effective therapy alternative to current treatments requiring surgery.
NDRM: 14.04 (-4.10)
NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
GlobeNewswire - Thu Dec 18, 6:00AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2014 and provided a corporate update.
NDRM: 14.04 (-4.10)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.68 (-0.33), ADMS: 17.37 (+0.31), TEVA: 57.51 (+0.54), ACOR: 40.87 (+0.23), PRTA: 20.76 (+0.07), NDRM: 14.04 (-4.10)
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
GlobeNewswire - Fri Dec 05, 7:53AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that Oded S. Lieberman, PhD, CEO will present at the Oppenheimer 25 Annual Healthcare Conference on December 10, 2014 at 8:35am ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's next-generation treatments for central nervous system disorders, including the company's flagship product candidates designed to treat moderate to severe Parkinson's disease. To access a live webcast of this presentation, please visit ir.neuroderm.com/. A replay will be available for one month following the presentation.
NDRM: 14.04 (-4.10)
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 31.68 (-0.33), ABBV: 65.44 (-0.86), NDRM: 14.04 (-4.10), NVS: 92.66 (-0.55)
Market News: Civeo Corp, Eagle Rock Energy Partners, Neuderm Ltd
at The Street - Wed Dec 31, 1:53PM CST
The stock markets in the United States fluctuated declined, wiping out earlier gains today–the last trading session for 2014. The markets were negatively impacted by the weakness of equities in ...
CVEO: 4.11 (+0.19), EROC: 2.20 (+0.18), NDRM: 14.04 (-4.10)
NeuroDerm (NDRM) Stock Plunges Today Following Tuesday's Gains
at The Street - Wed Dec 31, 1:16PM CST
Shares of NeuroDerm (NDRM) plummeted Wednesday as the stock sold off one day after it soared following the company's announcement of encouraging trial results for a treatment of Parkinson's disease.
NDRM: 14.04 (-4.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 12:05PM CST
FATE: 5.03 (-0.62), SIBC: 20.72 (+5.36), FUR: 15.59 (-2.32), DRAM: 1.70 (-0.23), NRX: 13.35 (+8.70), MEIL: 1.36 (+0.35), MIG: 8.46 (+1.33), BCLI: 4.76 (+0.88), ABAC: 1.73 (-0.18), GBR: 1.51 (+0.23), NDRM: 14.04 (-4.10), RCMT: 7.00 (-1.55), AGRX: 6.14 (-0.56), REN: 1.32 (+0.28), KEG: 1.67 (-0.19), LIME: 2.93 (+0.52), CALA: 20.20 (+1.89), CJJD: 2.90 (-0.25), CBMG: 12.91 (+1.39), GNI: 13.90 (-1.90)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 8:15AM CST
CYTK: 8.01 (+1.11), NEON: 3.38 (+0.30), ARWR: 7.38 (-0.19), NRX: 13.35 (+8.70), PEIX: 10.33 (-0.38), BCLI: 4.76 (+0.88), MIG: 8.46 (+1.33), NDRM: 14.04 (-4.10)
Spot the Potential Winners: Research Reports on SEACOR, Shanda Games, Neuroderm, Seadrill, and Lockheed Martin
PR Newswire - Wed Dec 31, 7:50AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including SEACOR (NYSE: CKH), Shanda Games (NASDAQ: GAME), Neuroderm (NASDAQ: NDRM) Seadrill (NYSE: SDRL), and Lockheed Martin (NYSE: LMT). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
LMT: 192.57 (-2.86), CKH: 73.81 (-0.12), GAME: 5.68 (-0.13), SDRL: 11.94 (+0.01), NDRM: 14.04 (-4.10)
Today's Market: Stocks Making Solid Moves Into New Year
Matthew Smith - at Seeking Alpha - Wed Dec 31, 7:49AM CST
NPD: 1.58 (-0.10), WAB: 86.89 (-1.17), CJJD: 2.90 (-0.25), AAPL: 110.38 (-2.14), NDRM: 14.04 (-4.10)
NeuroDerm up on drug data
at Investor's Business Daily - Tue Dec 30, 5:28PM CST
Positive midstage trial results for its Parkinson's disease candidate ND0612H lifted shares of NeuroDerm (NDRM), which bounced back from its flop stock market debut last month. The biotech said that a high-dose combo of standard Parkinson's drugs...
NDRM: 14.04 (-4.10)
Stocks Fall in Light Trading as Oil and Greece Weigh on Markets
at The Street - Tue Dec 30, 3:09PM CST
Oil and Greece were the focus of 2014's penultimate trading session in what was an otherwise quiet day.
GPRO: 63.22 (-2.18), HK: 1.78 (+0.05), ABX: 10.75 (-0.11), AKAM: 62.96 (-1.11), FCX: 23.36 (-0.22), NEM: 18.90 (-0.36), XNPT: 8.77 (unch), NDRM: 14.04 (-4.10), RDS.A: 66.95 (-0.41), KGC: 2.82 (+0.02), GLD: 113.58 (-1.62), CVEO: 4.11 (+0.19), BP: 38.12 (-0.24), ARCP: 9.05 (-0.06), YELP: 54.73 (+0.49), XLE: 79.16 (-0.60), GG: 18.52 (-0.07)
Market News: Neuroderm Ltd, Civeo Corp, Expedia Inc
at The Street - Tue Dec 30, 2:36PM CST
The stock markets in the United States dropped today. The S&P 500's seventh straight gain in December was trimmed by today's decline, according to Bloomberg. The S&P 500 reached a record-l...
EXPE: 85.36 (-0.61), CVEO: 4.11 (+0.19), NDRM: 14.04 (-4.10)
NeuroDerm Is A Good Play In Parkinson's Disease
Clinically Sound Investor - at Seeking Alpha - Tue Dec 30, 12:39PM CST
NDRM: 14.04 (-4.10)
NeuroDerm Rebounds On Parkinson's Disease Drug Data
at Investor's Business Daily - Tue Dec 30, 11:19AM CST
Recent biotech IPO NeuroDerm (NDRM) on Tuesday bounced back from its flop stock market debut last month after it reported positive midstage trial results for its Parkinson's disease candidate, with shares jumping more than 70%. NeuroDerm said...
IPXL: 31.68 (-0.33), ACOR: 40.87 (+0.23), NVS: 92.66 (-0.55), NDRM: 14.04 (-4.10)
NeuroDerm (NDRM) Stock Skyrockets to One-Year High After Encouraging Parkinson's Treatment Results
at The Street - Tue Dec 30, 9:07AM CST
Shares of NeuroDerm (NDRM) soared to a 52-week high in morning trading Tuesday after the Israeli company announced encouraging results from a trial for a treatment of Parkinson's disease.
NDRM: 14.04 (-4.10)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 8:11AM CST
JOB: 1.21 (-0.01), ARCP: 9.05 (-0.06), CJJD: 2.90 (-0.25), XNPT: 8.77 (unch), NDRM: 14.04 (-4.10)
NeuroDerm LD/CD candidates deliver high levodopa levels in PD patients in study
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 7:25AM CST
NDRM: 14.04 (-4.10)
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
GlobeNewswire - Tue Dec 30, 6:11AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that continuous, subcutaneous delivery of the company's proprietary liquid levodopa/carbidopa (LD/CD) product candidates, ND0612H and ND0612L, led to clinically-significant plasma levodopa levels. These results suggest that the high dose version, ND0612H, intended for severe Parkinson's disease patients, may provide an effective therapy alternative to current treatments requiring surgery.
NDRM: 14.04 (-4.10)
NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
GlobeNewswire - Thu Dec 18, 6:00AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2014 and provided a corporate update.
NDRM: 14.04 (-4.10)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.68 (-0.33), ADMS: 17.37 (+0.31), TEVA: 57.51 (+0.54), ACOR: 40.87 (+0.23), PRTA: 20.76 (+0.07), NDRM: 14.04 (-4.10)
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
GlobeNewswire - Fri Dec 05, 7:53AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that Oded S. Lieberman, PhD, CEO will present at the Oppenheimer 25 Annual Healthcare Conference on December 10, 2014 at 8:35am ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's next-generation treatments for central nervous system disorders, including the company's flagship product candidates designed to treat moderate to severe Parkinson's disease. To access a live webcast of this presentation, please visit ir.neuroderm.com/. A replay will be available for one month following the presentation.
NDRM: 14.04 (-4.10)
